\
&
Contact us
\
&
Contact us
Starts in 2 weeks from now
LocationOnline
ProgrammesThis fireside chat launches a new webinar series on the Apply AI Strategy, the EU strategy to accelerate the uptake of Artificial Intelligence in EU strategic sectors.
The Apply AI Strategy aims to foster an AI first policy to boost innovation, particularly among SMEs, and reinforce Europe's technological sovereignty by connecting world-class infrastructure, data, and testing facilities with the needs of key industrial sectors and the public sector, while taking into consideration the risks of the technology.
This webinar will provide a high-level overview of the Apply AI strategy's core pillars. It will be live streamed the Commission's YouTube channel. Both the recording and the slides will be avaliable after the session.
Find more information about this webinar and the upcoming Apply AI webinars.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
